KMT2A rearrangement is the prototypical cytogenetic finding among tr-AML patients exposed to topoisomerase II inhibitors, and the incidence of KMT2A rearrangement is higher in tr-ALL compared to dn-ALL 4,6. The gene discussed is KMT2A; the disease is acute myeloid leukemia.